CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
iBio expands collaboration with AzarGen to develop plant-made rituximab
iBio (NYSE AMERICAN:IBIO) advanced its collaboration with closely-held AzarGen Biotechnologies by initiating development of a plant-made rituximab for the South African market. iBio previously used its FastPharming...
Concert Pharma completes enrollment in second open label alopecia areata trial
Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...
SVB Leerink starts Axonics Modulation at OP; PT $45
SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...
TBIG starts Cellular Biomedicine at buy; PT $19
TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...
HCW ups Pluristem PT to $15.50 from $3.50 post reverse split
H.C. Wainwright raised its price target for Pluristem Therapeutics (NASDAQ:PSTI) to $15.50 from $3.50, reflecting a 10-for-1 reverse stock split and promising early results from a Phase 1 study. The stock closed at $4...
Dawson James starts BioCardia at buy; PT $24
Dawson James Securities launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $24 price target. The stock closed at $4.84 on Sept. 16. BioCardia is a developing two different cell therapy systems to...
Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials
Allena Pharmaceuticals (NASDAQ:ALNA) has completed enrollment in the first of two Phase 3 clinical trials of reloxaliase for the treatment of enteric hyperoxaluria. Enteric hyperoxaluria occurs when an underlying...
FDA AdCom votes to approve Aimmune’s PALFORZIA for peanut allergy
An advisory committee of the FDA voted to support the use of Aimmune Therapeutics’ (NASDAQ:AIMT) PALFORZIA in children and teens with peanut allergy. The committee voted seven-to-two that the efficacy data and eight-to...
Bellerophon gets FDA orphan drug designation for IPF therapy
Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. IPF is a progressive and fatal lung disease caused by the...
Just a few of the companies we’ve highlighted along the way
